LY353381.HCl: A novel raloxifene analog with improved SERM potency and efficacy in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 287, Issue 1, 1998, Pages 1-7

  Sato, Masahiko ^a   Turner, Charles H ^a,b   Wang, Tongyu ^a,b   Adrian, M Dee ^a   Rowley, Ellen ^a   Bryant, Henry U ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; BENZOTHIOPHENE DERIVATIVE; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; RALOXIFENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE ATROPHY; BONE DENSITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FEMALE; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RAT; TIBIA; UTERUS; UTERUS WEIGHT; YOUNG MODULUS;

EID: 0032462194     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Ashby J, Odum J and Foster JR (1997) Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Regul Toxicol Pharmacol 25(3):226-31.
2. Bain SD, Celino DL, Baily MC, Strachan MJ, Piggott JR, Labroo VM (1995) Centchroman, a non-steroidal antiestrogen, is a bone-specific estrogen agonist in the ovariectomized rat. Calcif Tissue Int 54:338 (Abstr.)
3. Black LJ, Jones CD and Facone JR (1983) Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32:1031-1036.
4. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CATE.rmine JD and Bryant HU (1994) Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
5. Bryant HU, Glasebrook AL, Knadler MP, Shetler PK, Short LL, Sato M, Thrasher KJ and Palkowitz AL (1997) LY353381. HCl: a highly potent, orally active selective estrogen receptor modulator. The Endocrine Society 79th Annual Meeting 548:P3-446 (Abstr.)
6. Bryant HU, Glasebrook A, Yang NN and Sato M (1996) A pharmacological review of raloxifene. J Bone Miner Metab 14:1-9.
7. Col NF, Eckman MH, Kras RH, Pauker SG, Goldberg RJ, Ross EM, Orr RK and Wong JB (1997) Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 277:1140-1147.
8. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M and Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1646.
9. Dupont WD and Page DL (1991) Menopausal estrogen replacement therapy and breast cancer. Arch Int Med 151:67-72.
10. Durbridge TC, Morris HA, Parsons AM, Parkinson IH, Moore RJ, Porter S, Need AG, Nordin Bec and Vern-Roberts B (1990) Progressive cancellous bone loss in rats after adrenalectomy and oophorectomy. Calcif Tiss Int 47:383-387.
11. Frost HM and Jee Wss (1992) On the rat model of human osteopenias and osteoporoses. Bone Miner 18:227-236.
12. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH and Speizer FE (1997) Postmenopausal hormone therapy and mortality. N Engl J Med 336:1769-1822.
13. Hammond CB, Jelovsek FR, Lee KL, Creasman WT and Parker RT (1979) Effects of long term estrogen therapy. I. Metabolic effects. Am J Obstet Gynecol 133:525-536.
14. Jordan VC, Allen KE and Dix CJ (1980) Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64:745-759.
15. Kalu DN (1991) The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175-192.
16. Kalu DN, Salerno E, Liu CC, Echon R, Ray M, Garza-Zapata M and Hollis BW (1991) A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner 15:109-124.
17. Kaufman RF and Bryant HU (1996) Selective estrogen receptor modulators. DN&P 8:531-539.
18. Ke HZ, Chen HK, Simmons HA, Qi H, Crawford DT, Pirie CM, Chidsey-Frink KL, Ma YF, Jee Wss and Thompson DD (1997) Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 20:31-39.
19. Lindsay R, Hart DM, Forrest C and Baird C (1980) Prevention of spinal osteoporosis in oophorectomized women. Lancet 2:1151-1154.
20. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP and DeMets DL (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856.
21. McDonnell DP, Clemm DL, Hermann T, Goldman ME and Pike JW (1995) Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endo 9:659-669.
22. Moon LY, Wakley GK and Turner RT (1991) Dose-dependent effects of tamoxifen on long bones in growing rats: Influence of ovarian status. Endocrinology 129:1568-1574.
23. Palkowitz AD, Glasebrook AL, Thrasher JK, Hauser KL, Short LL, Phillips L, Muehl BS, Sato M, Shetler PK, Cullinan GJ, Pell TR and Bryant HU (1997) Discovery and synthesis of [6-hydroxy-3-[4-(1-piperidinyl)-ethoxy-phenoxy]-2-(4-hydroxyphenyl-)benzo[b] thiophene: a novel, highly potent selective estrogen receptor modulator (SERM). J Med Chem 40:1407-1416.
24. Quigley Met, Martin PL, Curnier AM and Brooks P (1987) Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 156:1516-1523.
25. Sato M (1995) Comparative x-ray densitometry of bones from ovariectomized rats. Bone 17(Suppl 4):157S-162S.
26. Sato M and Bryant HU (1996) Raloxifene efficacy in nonreproductive and reproductive tissues in rat models in vivo and in vitro, in In vitro Biology of Sex Steroid Hormone Action (Kuramoto H and Gurpide E. eds) pp. 406-421, Churchill Livingstone, Tokyo.
27. Sato M, Bryant H, Iversen P, Helterbrand J, Smietana F, Bemis K, Higgs R, Owan I, Takano T and Burr D (1996a) Advantages of raloxifene over alendronate or estrogen on Non-reproductive and reproductive tissues in the long-term dosing of ovariectomized rats. JPET 279:298-305.
28. Sato M, Kim J, Short LL, Slemenda CW and Bryant HU (1995) Longitudinal and cross-sectional analysis of Raloxifene effects on tibiae from ovariectomized aged rats. JPET 272:1252-1259.
29. Sato M, McClintock C, Kim J, Turner C, Bryant H, Magee D and Slemenda C (1994) Dual-energy x-ray absorptiometry of Raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res 9:715-724.
30. Sato M, Rippy MK and Bryant HU (1996b) Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and non-reproductive tissues in ovariectomized rats. FASEB J 10:905-912
31. Sato M, Zeng GQ and Turner CH (1997) Biosynthetic human PTH (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology 10:4330-4337.
32. Smith DC, Prentice R, Thompson DJ and Herrmann WL (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293:1164-1167.
33. Stampfer MJ, Colditz GA, Willet WC, Manson JE, Rosner B, Speizer FE and Hennekens CH (1991) Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses' Health Study. N Engl J Med 325:756-762.
34. Steinberg KK, Thacker SB and Smith SC (1991) A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985-1990.
35. Turner CH and Burr DB (1993) Basic biomechanical measurments of bone: A tutorial. Bone 14:595-608.
36. Turner CH, Sato M and Bryant HU (1994) Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135:2001-2005
37. Turner RT, Vandersteenhoven JJ and Bell NH (1987) The effects of ovariectomy and 17β estradiol on cortical bone histomorphometry in growing rats. J Bone Miner Res 2:115-122.
38. Turner RT, Wakley GK, Hannon KS and Bell NH (1988) Tamoxifen inhibits osteoclast mediated resorption of trabecular bone in ovarian hormone deficient rats. Endocrinology 122:1146-1150.
39. Toolan BC, Shea M, Myers ER, Borchers RE, Seedor JG, Quartuccio H, Rodan G and Hayes WC (1992) Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res 12:1399-1406.
40. Vesey MP (1984) Exogenous hormones in the aetiology of cancer in women. J Roy Soc Med 77:542-549.
41. Weiss NS, Ure Cl, Ballard JH, Williams AR and Daling JR (1980) Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303:1195-1198.
42. Willson TM, Norris JD, Wagner BL, Asplin I, Baer P, Brown HR, Jones SA, Henke B, Sauls H, Wolfe S, Morris DC and McDonnell DP (1997) Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138: 3901-3911.45.
43. Wronski TJ, Cintron M, Doherty AL and Dann LM (1988) Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology 123:681-686.
44. Wronski TJ and Yen CF (1991) The ovariectomized rat as an animal model for postmenopausal bone loss. Cell and Mater S 1:69-74.
45. Wronski TH, Yen CF, Burton KW, Mehta RC, Newman PS, Soltis EE and DeLuca PP (1991) Skeletal effects of calcitonin on ovariectomized rats. Endocrinology 129: 2246-2250.
46. Ziel HK and Finkle WD (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293:1167-1170.